Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120092 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 | |
| SCHEMBL11927655 | 0.88 | EHMT2 (0.40) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 | |
| SCHEMBL31474406 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2APOLBSMN1; SMN2 | |
| SCHEMBL17758942 | 0.86 | ALDH1A1 (0.39) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 | |
| SCHEMBL18052248 | 0.86 | EHMT2 (0.38) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 | |
| SCHEMBL17283454 | 0.85 | HDAC1 (0.43) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 | |
| SCHEMBL16006021 | 0.85 | HDAC1 (0.39) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 | |
| SCHEMBL18726699 | 0.81 | EHMT2 (0.43) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 | |
| SCHEMBL18726707 | 0.80 | MMP2 (0.44) | ALDH1A1MAPTPOLBSMN1; SMN2HPGD | |
| SCHEMBL18651047 | 0.80 | KDM4E (0.35) | ALDH1A1HDAC1HDAC2EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719483-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES, ANTI-PD1/PD-L1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | Sanofi (FR) | 2026-04-08 | — | — | EP | claimed |
| EP-4676541-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES, ANTI-VEGFR-2 ANTIBODIES AND ANTI-PD1/PD-L1 ANTIBODIES | Sanofi (FR) | 2026-01-14 | — | — | EP | claimed |
| WO-2024251733-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES, ANTI-PD1/PD-L1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | SANOFI (FR) | 2024-12-12 | — | — | WO | claimed |
| EP-4440618-A1 | CEACAM5 ADC-ANTI-PD1/PD-L1 COMBINATION THERAPY | Sanofi (FR) | 2024-10-09 | — | — | EP | claimed |
| WO-2024184349-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES, ANTI-VEGFR-2 ANTIBODIES AND ANTI-PD1/PD-L1 ANTIBODIES | SANOFI (FR) | 2024-09-12 | — | — | WO | claimed |
| EP-4426736-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES AND ANTI-VEGFR-2 ANTIBODIES | Sanofi (FR) | 2024-09-11 | — | — | EP | claimed |
| CN-118574639-A | CEACAM5 ADC-anti-PD 1/PD-L1 combination therapy | 赛诺菲 | 2024-08-30 | — | — | CN | claimed |
| WO-2023099682-A1 | CEACAM5 ADC–ANTI-PD1/PD-L1 COMBINATION THERAPY | SANOFI (FR) | 2023-06-08 | — | — | WO | claimed |
| WO-2023079057-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES AND ANTI-VEGFR-2 ANTIBODIES | SANOFI (FR) | 2023-05-11 | — | — | WO | claimed |
| CN-115768484-A | Antitumor combinations containing anti-CEACAM 5 antibody conjugates and irinotecan | 赛诺菲 | 2023-03-07 | — | — | CN | claimed |
| EP-4138924-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFIRI | SANOFI (FR) | 2023-03-01 | — | — | EP | claimed |
| EP-4138926-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFOX | SANOFI (FR) | 2023-03-01 | — | — | EP | claimed |
| EP-4138925-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL | SANOFI (FR) | 2023-03-01 | — | — | EP | claimed |
| EP-4138927-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND CETUXIMAB | SANOFI (FR) | 2023-03-01 | — | — | EP | claimed |
| CN-115484989-A | Antitumor combinations containing anti-CEACAM 5 antibody conjugates, trifluridine and triflouracil | 赛诺菲 | 2022-12-16 | — | — | CN | claimed |
| CN-115427083-A | Antitumor combination comprising anti-CEACAM 5 antibody conjugate and cetuximab | 赛诺菲 | 2022-12-02 | — | — | CN | claimed |
| CN-115427082-A | Antitumor combinations comprising anti-CEACAM 5 antibody conjugates and FOLFOX | 赛诺菲 | 2022-12-02 | — | — | CN | claimed |
| CN-114173823-A | Use of anti-CEACAM 5 immunoconjugates for treating lung cancer | 赛诺菲 | 2022-03-11 | — | — | CN | claimed |
| WO-2026107136-A1 | ANTI-CEACAM5 ANTIBODY DRUG CONJUGATES FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-114173823-A | Use of anti-CEACAM 5 immunoconjugates for treating lung cancer | 赛诺菲 | 2022-03-11 | — | — | CN | disclosed |